Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jul 9:2019:6702870.
doi: 10.1155/2019/6702870. eCollection 2019.

Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature

Affiliations
Case Reports

Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature

Narciss Mobini et al. Case Rep Dermatol Med. .

Abstract

Recent emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of cancers and produced prolonged response by boosting the immune system against tumor cells. The primary target antigens are cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), a downregulator of T-cell activation, and programmed cell death-1 receptor (PD-1), a regulator of T-cell proliferation. This enhanced immune response can induce autoimmune adverse effects in many organs. Although skin toxicities are the most common, sarcoidal inflammation with exclusive cutaneous involvement is a rare occurrence with only 6 cases reported to date. We report 2 cases with unusual features. One patient is a female who was treated for metastatic renal cell carcinoma with combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). She developed deep nodules showing sarcoidal dermatitis and panniculitis on histopathologic exam. The second patient is a male with melanoma of eyelid conjunctiva who was treated prophylactically with ipilimumab. He presented with papules/plaques confined to black tattoos, where the biopsy revealed sarcoidal dermatitis. By a comprehensive literature review, we intend to raise awareness about this potential skin side effect in the growing number of patients receiving targeted immunotherapies. It is crucial to have a high index of suspicion and perform timely biopsies to implement appropriate management strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a), (b), (c). Deep dermal and mainly subcutaneous sarcoidal granulomata characterized by multinodular infiltrate of mono- and multinucleated epithelioid histiocytes with some lymphocytes (hematoxylin-eosin stain, magnifications 10 X, 10X, 20X, respectively).
Figure 2
Figure 2
(a), (b). Papulonodular lesions within the black tattoos in patient 2.
Figure 3
Figure 3
(a), (b). Sarcoidal-type granulomatous inflammation confined to the areas harboring black tattoo pigment (hematoxylin-eosin stain, magnifications 10 X, 20X, respectively).

References

    1. Hoffman L., Forschner A., Loquai C., et al. Cutaneous, gastrointestinal, hepatic,endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer. 2016;60:190–209. - PubMed
    1. Tetzlaff M. T., Jazaeri A. A., Torres-Cabala C. A., et al. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. Journal of Cutaneous Pathology. 2017;44(12):1080–1086. doi: 10.1111/cup.13044. - DOI - PubMed
    1. Curry J. L., Tetzlaff M. T., Nagarajan P., et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology. 2017;44(2):158–176. doi: 10.1111/cup.12858. - DOI - PubMed
    1. Cornejo C. M., Haun P., English J., Rosenbach M. Immune checkpoint inhibitors and the development of granulomatous reactions. Journal of the American Academy of Dermatology. 2018 - PubMed
    1. Collins L. K., Chapman M. S., Carter J. B., Samie F. H. Cutaneous adverse effects of the immune checkpoint inhibitors. Current Problems in Cancer. 2017;41(2):125–128. doi: 10.1016/j.currproblcancer.2016.12.001. - DOI - PubMed

Publication types

LinkOut - more resources